SCHEMBL23843622

SCHEMBL23843622

Cc1ccc(S(=O)(=O)NC(=O)C(C)(C)Oc2ccc3ccccc3c2)c(C)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAPGEF3 O95398 2/20 0.65
▸ PPARA Q07869 4/20 0.48
▸ ALDH1A1 P00352 4/20 0.44
▸ HPGD P15428 3/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ POLB P06746 3/20 0.43
▸ MEN1 O00255 3/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ GAA P10253 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ MAPT P10636 2/20 0.42
▸ ALOX12 P18054 1/20 0.42
▸ GFER P55789 1/20 0.42
▸ EPHX2 P34913 1/20 0.42
▸ LMNA P02545 2/20 0.42
▸ BLM P54132 1/20 0.42
▸ ATM Q13315 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ MEP1B Q16820 1/20 0.41
▸ MAP1LC3B Q9GZQ8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25462147 0.73 RAPGEF3 (0.89) RAPGEF3ALDH1A1POLBMEN1KMT2A
SCHEMBL25462131 0.72 RAPGEF3 (0.89) RAPGEF3ALDH1A1POLBMEN1KMT2A
SCHEMBL23843619 0.71 RAPGEF3 (0.65) RAPGEF3ALDH1A1HPGDPOLBMEN1
SCHEMBL5822856 0.69 PPARG (0.57) PPARAALDH1A1HSD17B10POLBMEN1
SCHEMBL30439580 0.69 PPARG (0.57) PPARAALDH1A1HSD17B10POLBMEN1
SCHEMBL25462255 0.69 RAPGEF3 (0.81) RAPGEF3ALDH1A1POLBMEN1KMT2A
SCHEMBL25186261 0.69 RAPGEF3 (0.80) RAPGEF3ALDH1A1HSD17B10POLBMEN1
SCHEMBL23843612 0.68 RAPGEF3 (0.80) RAPGEF3ALDH1A1HSD17B10POLBMEN1
SCHEMBL25182638 0.68 RAPGEF3 (0.80) RAPGEF3ALDH1A1HPGDPOLBMEN1
SCHEMBL30439576 0.68 RAPGEF3 (0.80) RAPGEF3ALDH1A1HPGDPOLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150929-A1 SELECTIVE NON-CYCLIC NUCLEOTIDE ACTIVATORS FOR THE CAMP SENSOR EPAC1 UNIV TEXAS (US) 2023-05-18 — — US disclosed
US-20230150929-A1 SELECTIVE NON-CYCLIC NUCLEOTIDE ACTIVATORS FOR THE CAMP SENSOR EPAC1 UNIV TEXAS (US) 2023-05-18 — — US disclosed
WO-2021188728-A1 SELECTIVE NON-CYCLIC NUCLEOTIDE ACTIVATORS FOR THE CAMP SENSOR EPAC1 THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-09-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150929-A1 SELECTIVE NON-CYCLIC NUCLEOTIDE ACTIVATORS FOR THE CAMP SENSOR EPAC1 CREB1, RAPGEF4, ATF4 RAPGEF3 4/4885PPARA 866/4885ALDH1A1 3629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback